Female pattern hair loss is the most common cause of hair loss in women — yet it is frequently underdiagnosed, underestimated, and undertreated. It is not simply a lesser version of male pattern baldness. It has its own distinct presentation, its own hormonal context, and increasingly, its own growing evidence base for effective intervention.
How Common Is It?
Female pattern hair loss (FPHL) affects an estimated 12% of women by age 29, rising to approximately 25–40% by age 70.1 Despite this prevalence, many women are not diagnosed until significant thinning has already occurred, partly because the gradual, diffuse nature of FPHL makes it easier to dismiss as normal ageing or stress-related shedding. Early recognition matters — treatment is considerably more effective at halting progression than reversing established loss.
How FPHL Differs from Male Pattern Hair Loss
The two conditions share a common underlying biology — androgen-mediated follicular miniaturisation in genetically susceptible individuals — but their clinical expression is strikingly different, and that distinction matters for diagnosis and management.
Pathophysiology
The precise cause of FPHL is not fully elucidated, but the central mechanism involves androgen-dependent follicular miniaturisation in women with genetic susceptibility.5 Dihydrotestosterone (DHT), the most potent endogenous androgen, binds to androgen receptors in the dermal papilla of scalp hair follicles and progressively shortens the anagen (growth) phase, reducing follicular diameter and hair shaft calibre over successive cycles.
A key distinction from male pattern hair loss is that women with FPHL frequently have normal circulating androgen levels. The pathology in many cases lies not in elevated DHT but in heightened follicular androgen receptor sensitivity or increased local 5α-reductase activity within susceptible follicles.6 This explains why anti-androgen therapies can be effective in women without overt hyperandrogenaemia. Oestrogen appears to play a protective role — its decline at menopause correlates with the acceleration of FPHL in many women, and the aromatase enzyme expressed in scalp follicles may provide some degree of local androgen buffering in premenopausal women.7
Many women with FPHL have entirely normal androgen blood tests. The problem is often not how much DHT is circulating — it is how sensitively their follicles respond to it.
Clinical Presentation: The Ludwig Scale
FPHL is most commonly graded using the Ludwig classification, which describes three progressive stages of central scalp thinning. This grading system guides both clinical communication and treatment intensity decisions.8
Minimal thinning over the crown. Widening of the central part is the earliest observable sign. Density reduction may only be apparent on close inspection or dermoscopy.
Appreciable widening of the central part with visible reduction in hair density over the vertex. The scalp becomes increasingly visible through the hair on the crown.
Near-complete thinning over the crown with sparse, vellus hair coverage. The frontal hairline is maintained, distinguishing even severe FPHL from male pattern baldness.
Diagnosis
FPHL is primarily a clinical diagnosis, but a structured approach is important to exclude other treatable causes of hair loss — particularly in younger women, where reversible aetiologies such as iron deficiency, thyroid dysfunction, or telogen effluvium are more commonly implicated.9
Clinical History
Duration and pattern of hair loss, family history of FPHL, menstrual and reproductive history, medications (particularly hormonal contraceptives, retinoids, anticoagulants), recent physical stressors, dietary history, and symptoms of hyperandrogenaemia (acne, hirsutism, irregular cycles).
Physical Examination
Assessment of hair distribution pattern (Ludwig grading), pull test for active shedding, evaluation for signs of hyperandrogenism, and examination of the entire scalp for co-existing conditions such as seborrhoeic dermatitis or scarring alopecia.
Trichoscopy (Dermoscopy)
Allows direct visualisation of follicular miniaturisation, hair shaft calibre variability (>20% variation is diagnostic), peripilar signs, and vellus hair predominance. Increasingly the standard of care in specialist hair loss assessment.10
Blood Tests
Full blood count, ferritin (iron stores), TSH, free androgen index, DHEAS, and prolactin should be considered — particularly in women under 50, those with irregular periods, or those with signs of hyperandrogenaemia. Vitamin D and zinc are sometimes assessed.
Scalp Biopsy
Reserved for cases where the diagnosis is uncertain or a scarring alopecia cannot be excluded. Histology typically demonstrates a reduced terminal-to-vellus ratio, follicular miniaturisation, and a mild perifollicular infiltrate without fibrosis.9
Treatment Options
Management of FPHL aims to halt progression, stimulate regrowth where possible, and address any contributing reversible factors. Treatment is long-term — effects are gradual, and cessation typically results in resumption of hair loss within months. Realistic expectations are an important part of the initial consultation.
Topical Minoxidil
First-line pharmacotherapy. FDA-approved at 2% for women (5% used off-label with greater efficacy). Applied to the scalp once or twice daily. Stimulates anagen phase and prolongs hair cycle duration. Response rates of 40–60% with consistent use.4
Oral Minoxidil
Off-label at doses of 0.5–2.5 mg daily. Increasingly used where topical therapy is poorly tolerated or where low follicular sulfotransferase activity limits topical response. Comparable or superior efficacy in randomised trials at low doses.11
Spironolactone
An aldosterone antagonist with anti-androgenic properties. Used at 100–200 mg daily for FPHL, particularly in women with evidence of androgen excess or postmenopausal women. Contraindicated in women of childbearing age without reliable contraception.12
Finasteride
A 5α-reductase type 2 inhibitor that reduces systemic DHT. Evidence for FPHL is most robust in postmenopausal women at doses of 1–2.5 mg daily. Absolutely contraindicated in pregnancy due to teratogenic risk to a male foetus.13
Low-Level Laser Therapy
TGA and FDA-cleared devices (combs, helmets) provide a non-pharmacological adjunct. Evidence supports modest improvement in hair density. Best used in combination with pharmacological therapy rather than as monotherapy.14
Platelet-Rich Plasma (PRP)
Intradermal injection of autologous growth factor concentrate. Growing evidence base supports improvement in hair density and calibre in FPHL. Typically requires a series of sessions and maintenance treatment.15
Intradermal Dutasteride
Mesotherapy with dutasteride delivers high local concentrations of the dual 5α-reductase inhibitor directly to the follicular microenvironment while minimising systemic exposure. A viable option in premenopausal women where oral anti-androgens would otherwise be contraindicated. Emerging randomised evidence supports efficacy comparable to topical and oral alternatives.17
| Treatment | Typical Dose / Use | Key Consideration |
|---|---|---|
| Topical minoxidil 2% | 1 mL twice daily to scalp | FDA-approved first-line; OTC available |
| Topical minoxidil 5% | 1 mL once daily to scalp | Greater efficacy; off-label in women |
| Oral minoxidil | 0.5–2.5 mg once daily | Off-label; requires medical supervision11 |
| Spironolactone | 100–200 mg daily | Avoid in pregnancy; monitor potassium12 |
| Finasteride | 1–2.5 mg daily | Postmenopausal use preferred; contraindicated in pregnancy13 |
| Dutasteride oral | 0.5 mg daily (off-label) | Inhibits type 1 and 2 5α-reductase; emerging evidence in women13 |
| Dutasteride intradermal | 0.5–2.5 mg per session, every 1–3 months | Mesotherapy; high local follicular concentration; lower systemic exposure; suitable in premenopausal women17 |
The Psychological Dimension
The psychosocial burden of FPHL is substantial and should not be minimised in clinical encounters. Hair carries profound social and personal significance for women across all cultures, and its loss is frequently associated with grief, loss of identity, reduced self-esteem, social withdrawal, and anxiety.3 Studies consistently demonstrate that the psychological impact of hair loss in women is disproportionately greater than in men, even when objective severity is equivalent.16
A sensitive, unhurried consultation — one that validates the patient's experience before moving to management options — is itself therapeutic. Women who feel heard and who understand the nature of their condition are more likely to adhere to long-term treatment and to maintain realistic but hopeful expectations. Where psychological distress is significant, formal referral to psychology or psychiatry should be part of the management plan, not an afterthought.
It is also worth emphasising to patients that FPHL, unlike many other forms of hair loss, rarely results in complete baldness. The preservation of the frontal hairline and the typically moderate ceiling of progression mean that the goal of treatment — stabilisation and modest improvement — is realistic and achievable for the majority of women who seek timely intervention.
Conclusion
Female pattern hair loss is common, progressive, and amenable to treatment — but it demands a more nuanced clinical approach than simply applying the same framework used for men. Understanding that normal androgen levels do not exclude the diagnosis, that oestrogen decline accelerates the condition, and that the psychological impact is significant and deserves direct acknowledgement are all prerequisites for managing FPHL well. Effective treatment exists. The goal is to find it early enough to make the most of it.
References
- Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5–15.
- Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297–304.
- Reid EE, Haley AC, Bhatt DL, et al. Clinical severity does not adequately capture the impact of alopecia areata on quality of life. J Am Acad Dermatol. 2012;66(2):e1–e9.
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385.
- Sinclair R, Patel M, Dawber RP, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011;165(Suppl 3):12–18.
- Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19(5 Pt 1):831–836.
- Ohnemus U, Uenalan M, Inzunza J, et al. The hair follicle as an estrogen target and source. Endocr Rev. 2006;27(6):677–706.
- Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247–254.
- Whiting DA. Histopathology of female androgenetic alopecia. Dermatol Clin. 2010;28(3):581–590.
- Rudnicka L, Olszewska M, Rakowska A, et al. Trichoscopy: a new method for diagnosing hair loss. J Drugs Dermatol. 2008;7(7):651–654.
- Penha MA, Shapiro J, Lartey RT, et al. Oral minoxidil versus topical minoxidil for androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(2):156–163.
- Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466–473.
- Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298–302.
- Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144–151.
- Gentile P, Garcovich S, Bielli A, et al. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4(11):1317–1323.
- Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001;19(2):161–166.
- Saceda-Corralo D, Moreno-Arrones OM, Rodrigues-Barata AR, et al. Mesotherapy with dutasteride in the treatment of androgenetic alopecia: a retrospective study with 16 months of follow-up. J Cosmet Dermatol. 2020;19(10):2630–2635.